Chardan Capital reaffirmed their buy rating on shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) in a report issued on Wednesday morning, Benzinga reports. Chardan Capital currently has a $23.00 price objective on the stock.
Several other analysts have also recently issued reports on the company. HC Wainwright reduced their price objective on Lexeo Therapeutics from $22.00 to $21.00 and set a buy rating on the stock in a research note on Tuesday. Royal Bank of Canada restated an outperform rating and issued a $24.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday. Baird R W upgraded Lexeo Therapeutics to a strong-buy rating in a research note on Thursday, June 13th. Finally, Robert W. Baird began coverage on Lexeo Therapeutics in a research note on Thursday, June 13th. They issued an outperform rating and a $28.00 price target on the stock. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Lexeo Therapeutics presently has an average rating of Buy and an average price target of $22.14.
Check Out Our Latest Stock Analysis on LXEO
Lexeo Therapeutics Trading Up 2.6 %
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.64) EPS for the quarter, hitting the consensus estimate of ($0.64). On average, research analysts anticipate that Lexeo Therapeutics will post -2.65 EPS for the current fiscal year.
Insiders Place Their Bets
In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $11.53, for a total transaction of $57,650.00. Following the transaction, the chief executive officer now owns 120,695 shares of the company’s stock, valued at $1,391,613.35. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 4.50% of the company’s stock.
Hedge Funds Weigh In On Lexeo Therapeutics
Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new position in shares of Lexeo Therapeutics during the first quarter worth about $75,000. American International Group Inc. purchased a new position in shares of Lexeo Therapeutics during the first quarter worth about $79,000. Rhumbline Advisers grew its holdings in shares of Lexeo Therapeutics by 37.3% during the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after buying an additional 3,627 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Lexeo Therapeutics by 12.3% during the second quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock worth $510,000 after buying an additional 3,483 shares during the last quarter. Finally, Cornell University purchased a new position in shares of Lexeo Therapeutics during the first quarter worth about $1,980,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.
Lexeo Therapeutics Company Profile
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Featured Stories
- Five stocks we like better than Lexeo Therapeutics
- High Flyers: 3 Natural Gas Stocks for March 2022
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Walmart Stock: Buy the Rip or Wait for the Dip?
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 Stocks to Buy for a Soft Landing, If There Is One
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.